TP53 and diffuse large B-cell lymphoma: In recent years, high-throughput genomic studies further identified recurrent genetic alterations within the key disease-driving genes/pathways in DLBCL, such as BCL6 and MYC, epigenetic modifiers, p53/DNA damage response pathway, B cell receptor (BCR)/NF-κB-, NOTCH- and JAK-STAT-signaling pathways as well as genes related to antigen presentation and immune evasion.3